Noubar Afeyan

Director at Generate Biomedicines · 17 reported transactions in 2 companies · latest trade May 21, 2026

Their record

Across their whole record, 1 purchase can be measured; 1 did better than the S&P 500 over the next 6 months.

Typical move +32.5%, S&P 500 +11.6% over the same days.

May 21, 2026 · MRNA

$433.9K

S&P 500 +3.6%thru Oct 28

Mar 2, 2026 · GENB

$25M

S&P 500 +12.1%thru Oct 27

Mar 2, 2026 · GENB

$25M

S&P 500 +12.1%thru Oct 27

Mar 2, 2026 · GENB

$25M

S&P 500 +12.1%thru Oct 27

Newest 10 of 17 transactionsPro adds every trade with how it did, their holdings and the money-flow chartPro is $29 a month

Built from their public trade reports and market prices: past moves, not predictions or advice.

Director at Generate Biomedicines · 17 reported transactions in 2 companies · latest trade May 21, 2026

Across their whole record, 1 purchase can be measured; 1 did better than the S&P 500 over the next 6 months.

Typical move +32.5%, S&P 500 +11.6% over the same days.